Introduction: Sensory conflicts in the vestibular system lead to motion sickness of which space motion sickness (SMS) is a special case. SMS affects up to 70% of the astronauts during the first 3 days in space. The search for effective countermeasures has led to several nonpharmacological and pharmacological approaches. The current study focuses on the effects of lorazepam (1 mg), meclizine (25 mg), promethazine (25 mg), and scopolamine (0.4 mg) on the vestibular system, with special focus on the canal and otolith functions separately. Methods: The study had a placebo-controlled, single blind, repeated measures design. Sixteen healthy volunteers were subjected to a total of 7 test sessions, the first and last being without intake of medication. Semicircular canal function was evaluated by means of electronystagmography and otolith function with unilateral centrifugation. The horizontal semicircular canal function was characterized by the vestibulo-ocular reflex (VOR) gain measured during earth vertical axis rotation as well as the total caloric response. The function of the utricles was represented by the utricular sensitivity, reflecting the ocular counter roll relative to the virtual induced head tilt. Results: Promethazine significantly decreased the semicircular canal and utricular parameters. Both scopolamine and lorazepam caused only a decrease in the utricular sensitivity, whereas meclizine only decreased the semicircular canal-induced VOR gain. Discussion: The results show that the drugs affected different areas of the vestibular system and that the effects can thus be attributed to the specific pharmacological properties of each drug. Meclizine, as an antihistaminergic and weak anticholinergic drug, only affected the VOR gain, suggesting a central action on the medial vestibular nucleus. The same site of action is suggested for the anticholinergic scopolamine since acetylcholine receptors are present and utricular fibers terminate here. The global vestibular suppression caused by promethazine is probably a consequence of its anticholinergic, antihistaminergic, and antidopaminergic properties. Based on the fact that lorazepam increased the affinity of gamma-aminobutyric acid (GABA) for the GABAA-receptor and its effects on the utriculi, the site of action seems to be the lateral vestibular nucleus. Conclusion: Meclizine, scopolamine, and lorazepam selectively suppress specific parts of the vestibular system. Selective suppression of different parts of the vestibular system may be more beneficial for alleviating (space) motion sickness than general suppressive agents. Additionally, this knowledge may help the clinician in his therapeutic management of patients with either semicircular canal or otolith dysfunction.

Keywords:
Drugs, Vestibular system, Lorazepam, Scopolamine, Promethazine, Meclizine, Motion sickness
1.
Angelaki DE, McHenry MQ, Dickman JD, Newlands SD, Hess BJ: Computation of inertial motion: neural strategies to resolve ambiguous otolith information. J Neurosci 1999;19:316–327.
2.
Bagian JP: First intramuscular administration in the US Space Program. J Clin Pharmacol 1991;31:920.
3.
Barmack NH: Central vestibular system: vestibular nuclei and posterior cerebellum. Brain Res Bull 2003;60:511–541.
4.
Barton JJ, Huaman AG, Sharpe JA: Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: a double-blind, randomized trial of three intravenous drugs. Ann Neurol 1994;35:319–325.
5.
Bles W, de Graaf B, Bos JE, Groen E, Krol JR: A sustained hyper-g load as a tool to simulate space sickness. J Gravit Physiol 1997;4:1–4.
6.
Bonham AC, Hasser EM: Area postrema and aortic or vagal afferents converge to excite cells in nucleus tractus solitarius. Am J Physiol 1993;264:H1674–H1685.
7.
Bouthenet ML, Ruat M, Sales N, Garbarg M, Schwartz JC: A detailed mapping of histamine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I]iodobolpyramine. Neuroscience 1988;26:553–600.
8.
Clarke AH, Schonfeld U, Helling K: Unilateral examination of utricle and saccule function. J Vestib Res 2003;13:215–225.
9.
Davis JR, Jennings RT, Beck BG: Comparison of treatment strategies for space motion sickness. Microgravity Q 1992;2:173–177.
10.
Davis JR, Jennings RT, Beck BG, Bagian JP: Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993;64:230–233.
11.
Davis JR, Vanderploeg JM, Santy PA, Jennings RT, Stewart DF: Space motion sickness during 24 flights of the space shuttle. Aviat Space Environ Med 1988;59:1185–1189.
12.
de Waele C, Muhlethaler M, Vidal PP: Neurochemistry of the central vestibular pathways. Brain Res Brain Res Rev 1995;20:24–46.
13.
Dornhoffer J, Chelonis JJ, Blake D: Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness. Otol Neurotol 2004;25:740–745.
14.
Furman JM, Cass SP: Vestibular anatomy and physiology; in Furman JM, Cass SP (eds): Vestibular Disorders, a Case-Study Approach. New York, Oxford University Press, 2003, pp 3–15.
15.
Hain TC, Uddin M: Pharmacological treatment of vertigo. CNS Drugs 2003;17:85–100.
16.
Ito J, Matsuoka I, Sasa M, Fujimoto S, Takaori S: Electrophysiologic evidence for involvement of acetylcholine as a neurotransmitter in the lateral vestibular nucleus. Otolaryngol Head Neck Surg 1981;89:1025–1029.
17.
Jones EG: Neurotransmitters in the cerebral cortex. J Neurosurg 1986;65:135–153.
18.
Kirsten EB, Sharma JN: Microiontophoresis of acetylcholine, histamine and their antagonists on neurones in the medial and lateral vestibular nuclei of the cat. Neuropharmacology 1976;15:743–753.
19.
Koga T, Fukuda H: Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992;14:166–179.
20.
Kohl RL, Homick JL: Motion sickness: a modulatory role for the central cholinergic nervous system. Neurosci Biobehav Rev 1983;7:73–85.
21.
Lackner JR, Dizio P: Space motion sickness. Exp Brain Res 2006;175:377–399.
22.
Leigh RJ, Zee DS: The vestibular-optokinetic system; in Leigh RJ, Zee DS (eds): The Neurology of Eye Movements. New York, Oxford University Press, 1999, pp 19–89.
23.
Matsuoka I, Domino EF: Cholinergic mechanisms in the cat vestibular system. Neuropharmacology 1975;14:201–210.
24.
McClure JA, Lycett P, Baskerville JC: Diazepam as an anti-motion sickness drug. J Otolaryngol 1982;11:253–259.
25.
Nooij SA, Vanspauwen R, Bos JE, Wuyts FL: A re-investigation of the role of utricular asymmetries in space motion sickness. J Vestib Res 2011;21:141–151.
26.
Oman CM: Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990;68:294–303.
27.
Petrosini L, Dell’Anna ME: Vestibular compensation is affected by treatment with dopamine active agents. Arch Ital Biol 1993;131:159–171.
28.
Putcha L: Pharmacotherapeutics in space. J Gravit Physiol 1999;6:165–168.
29.
Pyykko I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG: The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med 1985a;56:777–782.
30.
Pyykko I, Schalen L, Jantti V: Transdermally administered scopolamine vs. dimenhydrinate. 1. Effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol 1985b;99:588–596.
31.
Pyykko I, Schalen L, Matsuoka I: Transdermally administered scopolamine vs. dimenhydrinate. 2. Effect on different types of nystagmus. Acta Otolaryngol 1985c;99:597–604.
32.
Raphan T, Cohen B: How does the vestibulo-ocular reflex work?; in Baloh RW, Halmagyi GM (eds): Disorders of the Vestibular System. New York, Oxford University Press, 1996, pp 20–47.
33.
Reason JT: Motion sickness adaptation: a neural mismatch model. J R Soc Med 1978;71:819–829.
34.
Reason JT, Brand JJ: Preventive measures; in Reason JT, Brand JJ (eds): Motion Sickness. London, Academic Press, 1975, pp 210–240.
35.
Reschke MF, Bloomberg JJ, Harm DL, Paloski WH, Layne C, McDonald V: Posture, locomotion, spatial orientation, and motion sickness as a function of space flight. Brain Res Brain Res Rev 1998;28:102–117.
36.
Schubert MC, Shepard NT: Practical anatomy and physiology of the vestibular system; in Jacobson GP, Shepard NT (eds): Balance Function Assessment and Management. San Diego, Plural Publishing, 2008, pp 1–26.
37.
Serafin M, de Waele C, Khateb A, Vidal PP, Muhlethaler M: Medial vestibular nucleus in the guinea-pig. 1. Intrinsic membrane properties in brainstem slices. Exp Brain Res 1991;84:417–425.
38.
Serafin M, Khateb A, Waele C: In vitro properties of medial vestibular neurons; in Shimazu H, Shinoda Y (eds): Vestibular and Brain Stem Control of Eye, Head and Body Movements. Basel, Karger, 1992, pp 111–121.
39.
Shojaku H, Watanabe Y, Ito M, Mizukoshi K, Yajima K, Sekiguchi C: Effect of transdermally administered scopolamine on the vestibular system in humans. Acta Otolaryngol Suppl 1993;504:41–45.
40.
Shupak A, Gordon CR: Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006;77:1213–1223.
41.
Souvestre PA, Blaber AP, Landrock CK: Space motion sickness: the sensory motor controls and cardiovascular correlation. Acta Astronaut 2008;63:745–757.
42.
Steiner FA, Weber G: The control of vestibularly excitable neurons of the brain stem by electrophoretically administered acetylcholine. Helv Physiol Pharmacol Acta 1964;22:C44–C46.
43.
Van der Stappen A, Wuyts FL, Van de Heyning PH: Computerized electronystagmography: normative data revisited. Acta Otolaryngol 2000;120:724–730.
44.
von Baumgarten RJ, Thumler R: A model for vestibular function in altered gravitational states. Life Sci Space Res 1979;17:161–170.
45.
Wang JJ, Dutia MB: Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Exp Brain Res 1995;105:18–24.
46.
Wood CD: Pharmacological countermeasures against motion sickness; in Crampton GH (ed): Motion and Space Sickness. CRC Press, 1990, pp 343–352.
47.
Wood CD, Graybiel A: Theory of antimotion sickness drug mechanisms. Aerosp Med 1972;43:249–252.
48.
Wuyts FL, Hoppenbrouwers M, Pauwels G, Van de Heyning PH: Utricular sensitivity and preponderance assessed by the unilateral centrifugation test. J Vestib Res 2003;13:227–234.
49.
Yamamoto C: Pharmacologic studies of norepinephrine, acetylcholine and related compounds on neurons in Deiters’ nucleus and the cerebellum. J Pharmacol Exp Ther 1967;156:39–47.
50.
Yates BJ, Grelot L, Kerman IA, Balaban CD, Jakus J, Miller AD: Organization of vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 1994;267:R974–R983.
51.
Yates BJ, Miller AD, Lucot JB: Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull 1998;47:395–406.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.